The pharmacokinetic and bioavailability of Cbl-b inhibitors is currently under investigation and future work will focus on evaluating the compounds anti-tumor activity in vivo in pre-clinical models and their potential clinical development. This evidence concerns the gene CBLB and neoplasm.